Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.2B | $217M | $73M | $257M | 3.8% | 5.2% | -56.3% |
| 2024 | $1.2B | $313M | $168M | $236M | 8.1% | 2.0% | -41.1% |
| 2023 | $1.1B | $457M | $285M | $216M | 14.5% | 2.8% | 4.9% |
| 2022 | $1.1B | $414M | $272M | $280M | 16.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1,105.60 | 1,136.70 | 1,159.06 | 1,219.64 |
| Cost Of Revenue | 349.10 | 366.89 | 389.34 | 429.36 |
| Gross Profit | 756.50 | 769.82 | 769.72 | 790.27 |
| Operating Expense | 460.67 | 478.82 | 523.32 | 547.47 |
| Operating Income | 295.83 | 291 | 246.40 | 242.80 |
| EBITDA | 413.76 | 457.11 | 313.14 | 216.88 |
| EBIT | 312.70 | 349.87 | 201.42 | 106.97 |
| Pretax Income | 301.39 | 338.66 | 185.69 | 98.46 |
| Tax Provision | 38.29 | 53.22 | 17.58 | 25.06 |
| Net Income | 272.05 | 285.26 | 168.10 | 73.40 |
| Net Income Common Stockholders | 271.93 | 285.19 | 168.07 | 73.36 |
| Total Expenses | 809.77 | 845.70 | 912.66 | 976.83 |
| Interest Expense | 11.31 | 11.22 | 15.74 | 8.51 |
| Interest Income | 0.79 | 3.41 | 3.32 | 3.89 |
| Research And Development | 87.14 | 92.49 | 96.66 | 99.50 |
| Selling General And Administration | 339 | 352.44 | 393.32 | 415.10 |
| Normalized EBITDA | 399.15 | 400.97 | 354.92 | 357.57 |
| Normalized Income | 259.29 | 237.94 | 205.92 | 178.22 |
| Market Cap | 8,477.42 | 8,477.42 | 8,477.42 | 8,477.42 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Bio-Techne Corporationthis co. | TECH | $8.5B | 115.50β premium | 4.42 | 3.8% | 40.39 |
| Revvity, Inc. | RVTY | $10.1B | 40.22 | 1.34 | 3.3% | 15.90 |
| Molina Healthcare, Inc. | MOH | $9.3B | 19.42 | 2.25 | 11.6% | 9.09 |
| Krystal Biotech, Inc. | KRYS | $7.9B | 39.16 | 6.58 | 16.8% | 44.89 |
| Alkermes plc | ALKS | $5.5B |
| 22.97 |
| 3.05 |
| 13.3% |
| 15.81 |
| PTC Therapeutics, Inc. | PTCT | $5.4B | 8.29 | -27.55 | -332.5% | 8.31 |
| TG Therapeutics, Inc. | TGTX | $5.3B | 13.08 | 9.02 | 69.0% | 44.82 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.1B | 233.78 | 14.14 | 6.0% | 74.89 |
| Corcept Therapeutics Incorporated | CORT | $4.8B | 49.62 | 7.63 | 15.4% | 103.46 |
| Peer Median | - | 31.07 | 4.81 | 12.4% | 30.36 | |